Compare · LYRA vs SYK
LYRA vs SYK
Side-by-side comparison of Lyra Therapeutics Inc. (LYRA) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LYRA and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 2755.8x LYRA ($45.5M).
- Over the past year, LYRA is down 89.9% and SYK is down 10.8% - SYK leads by 79.2 points.
- SYK has been more active in the news (5 items in the past 4 weeks vs 4 for LYRA).
- SYK has more recent analyst coverage (25 ratings vs 7 for LYRA).
- Company
- Lyra Therapeutics Inc.
- Stryker Corporation
- Price
- $0.49-61.33%
- $327.50-0.63%
- Market cap
- $45.5M
- $125.43B
- 1M return
- +0.00%
- -0.03%
- 1Y return
- -89.93%
- -10.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 5
- Recent ratings
- 7
- 25
Lyra Therapeutics Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest LYRA
- SEC Form 25 filed by Lyra Therapeutics Inc.
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- SEC Form 4 filed by Palasis Maria
- SEC Form 4 filed by Cavalier Jason
- SEC Form 10-K filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew